Organization
Immunocore, LLC, Rockville, MD
1 abstract
Abstract
Phase 1 safety and efficacy of IMC-F106C, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM).Org: The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, CA, HCA Healthcare global Sarah Cannon Research Institute, London, United Kingdom, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, University of Chicago, Comprehensive Cancer Center, Chicago, IL, Jefferson Medical College, Philadelphia, PA,